Clinical trials

Clinical trials are available at Allina Health Cancer Institute Coon Rapids, Minneapolis, & St. Paul unless noted otherwise.

Breast Cancer 

ASCENT-05 (Gilead GS-US-595-6184): A randomized, open-label, phase 3 study of adjuvant sacituzumab govitecan and pembrolizumab vs treatment of physician’s choice in patients with TNBC who have residual disease after surgery and neoadjuvant therapy (PI Krie).

ELAINE 3 (Sermonix SMX22-002): A phase 3, open label, randomized, multicenter study comparing the efficacy and safety of the combination of lasofoxifene and abemaciclib to the combination of fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation (PI Perez).

ELEGANT (Stemline STML-ELA-0422): A global, multicenter, randomized, open-label phase 3 study of elacestrant versus standard endocrine therapy in women and men with node-positive, ER+, HER2-, early breast cancer with high risk of recurrence (PI Carlson).

EMBER-4 J2J-MC-JZLH: A randomized, open-label, phase 3 study of adjuvant imlunestrant vs standard adjuvant endocrine therapy in patients who have previously received 2 to 5 years of adjuvant endocrine therapy for ER+, HER2- early breast cancer with an increased risk of recurrence (PI Krie).

FOURLIGHT-3 (Pfizer C4391024): Opening soon An interventional, open-label, randomized, multicenter phase 3 study of PF-07220060 plus letrozole compared to CDK4/6 inhibitor plus letrozole in participants over 18 years of age with HR+, HER2- advanced/metastatic breast cancer who have not received any prior systemic anticancer treatment for advanced/metastatic disease (PI Krie).

Merck MK2870-011: Opening soon A phase 3, randomized, open-label study comparing efficacy and safety of sacituzumab tirumotecan (sac-TMT, MK-2870) as a monotherapy and in combination with pembrolizumab (MK-3475) versus treatment of physician’s choice in participants with previously untreated locally recurrent unresectable or metastatic triple-negative breast cancer expressing PD-L1 at CPS less than 10 (TroFuse-011) (PI Krie).

TROPION-Breast04 (AZ D926QC00001): Closing soon A phase 3, open-label, randomized study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab with or without chemotherapy versus neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy for the treatment of adult patients with previously untreated triple-negative or hormone receptor-low/HER2-negative breast cancer (PI Perez). 

Colorectal Cancer

BioNTech BNT122-01: A phase 2, open-label, randomized study to compare the efficacy of RO7198457 versus watchful waiting in resected, stage II (high risk) and stage III colorectal cancer patients who are ctDNA positive following resection (PI Hubbard). *Only available in Minneapolis and St. Paul; Main cohort closed - CLM cohort open

Hematologic Cancer

AbbVie M22-716: A Phase 1, open-label study to determine the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in participants with relapsed or refractory (R/R) B-cell malignancies (PI He). *Only available in Minneapolis; 2.5 mg/kg cohort open for backfill; 5mg/kg cohort open for backfill; 10mg/kg cohort closed; 15 mg/kg cohort open

GOLSEEK-1 (BMS CA073-1020): A phase 3, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of golcadomide plus R-CHOP chemotherapy vs placebo plus R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (PI He).

Pfizer C4971006: Phase 1b/2, open-label study of PF-07901801 in combination with glofitamab after a fixed, single dose of obinutuzumab in participants with relapsed/refractory diffuse large B-cell lymphoma not eligible for stem cell transplantation (PI He). *Only available in Minneapolis; Phase 2 dose optimization open

Syndax SNDX-5613-0708: A phase 1, open-label, dose-escalation, and dose-expansion study to evaluate safety, tolerability, and clinical activity of SNDX-5613 (Revumenib) in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemias harboring alterations in lysine-specific methyltransferase 2A (KMT2A/MLL), nucleophosmin 1(NPM1), and nucleoporin 98 (NUP98) genes (PI He). *Only available in Minneapolis; Dose level 2 open; dose level 1 open for backfill

Lung Cancer 

 AZ PAC8 D9075C00001: Phase 3, randomized, double-blind, placebo-controlled, multicenter, international study of durvalumab plus domvanalimab (AB154) in participants with locally advanced (stage 3), unresectable NSCLC who have not progressed following definitive platinum-based concurrent chemoradiation therapy (PI Fares).

Merck MK-2870-019: Phase 3, randomized, open-label study of adjuvant pembrolizumab with or without MK-2870 in participants with resectable stage II to IIIB (N2) non-small cell lung cancer not achieving pCR after receiving neoadjuvant pembrolizumab with platinum-based doublet chemotherapy followed by surgery (PI Fares).

Merck MK-3475-D46: Phase 3, randomized, open-label, multicenter, active-comparator-controlled clinical study of pembrolizumab (MK-3475) in combination with sacituzumab govitecan versus pembrolizumab (MK-3475) monotherapy as first-line treatment in participants with PD-L1 TPS greater than or equal to 50% metastatic non-small cell lung cancer (PI Fares).

Merck MK-2870-007: Phase 3, randomized, open-label study of MK-2870 in combination with pembrolizumab compared to pembrolizumab monotherapy in the first-line treatment of participants with metastatic non-small cell lung cancer with PD-L1 TPS greater than or equal to 50% (PI Fares).

Merck MK-2870-023: Phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance MK-2870 in the first-line treatment of metastatic squamous cell lung cancer regardless of PD-L1 expression (PI Fares).

SUNRAY-01 Eli Lilly J3M-MC-JZQB: A global pivotal study in participants with KRAS G12C-mutant, locally advanced or metastatic non-small cell lung cancer comparing first-line treatment of olomorasib and pembrolizumab vs placebo and pembrolizumab in those with PD-L1 expression ≥50% or olomorasib and pembrolizumab, pemetrexed, platinum vs placebo and pembrolizumab, pemetrexed, platinum regardless of PD-L1 expression (PI Fares). *Part A/B open

Seagen SGNB6A-001: A phase 1 study to evaluate the safety and tolerability of SGN-B6A as monotherapy in previously treated, docetaxel-naive, squamous cell lung cancer (Part B) or SGN-B6A in combination with pembrolizumab +/- platinum chemotherapy in 1L metastatic or unresectable non-small cell lunger cancer and metastatic or recurrent head and neck squamous cell carcinoma (Parts C and D) (PI Fares). *Parts C and D closed until further notice 

TROPION-Lung 12 (AZ D926TC00001): A phase 3, randomized, open-label, global study of adjuvant datopotamab deruxtecan (Dato-DXd) in combination with rilvegostomig or rilvegostomig monotherapy versus standard of care, following complete tumor resection, in participants with stage I adenocarcinoma non-small cell lung cancer who are ctDNA-positive or have high-risk pathological features (PI Fares).

TROPION-Lung 14 (AZ D516NC00001): Opening soon A Phase 3, open-label, randomized study of osimertinib with or without Dato-DXd, as first-line treatment in participants with EGFR mutationpositive, locally advanced or metastatic non-small cell lung cancer (PI Leach). 

Melanoma

Regeneron R3767-ONC-22122: A phase 3 study of fixed dose combinations of fianlimab and cemiplimab versus relatlimab and nivolumab in participants with unresectable or metastatic melanoma (PI Fares). 

Metastatic Brain Lesions

ROADS GTM-102: Phase 3, randomized, controlled trial of post-surgical stereotactic radiotherapy (SRT) versus surgically targeted radiation therapy (STaRT) with GammaTile for treatment of newly diagnosed metastatic brain tumors (PI Nagib). *Only available in Minneapolis (contact: Jennifer Murwin 612-863-1281) 

Diagnostic Studies

Adela EDMRD-001 CAMPERR: cfDNA assay multicenter prospective observational validation for early cancer detection, minimal residual disease, and relapse (CAMPERR) (PI Gorse).

Astrin 2021L0021: Non-therapeutic, proof of concept study seeking to detect and isolate circulating tumor cells from the blood samples of treatment naive patients. Now enrolling patients with a new
diagnosis of one of the following cancers: breast, brain, colorectal, esophageal, gastric, kidney, liver, oropharyngeal, pancreas, rectal and no prior treatment (PI He).

Exact Sciences 2021-05: Whole blood and tumor tissue specimen collection from subjects who either have a diagnosis of cancer or recurrent cancer to evaluate biomarkers (PI Torgerson).

Exact Sciences 2024-02: Opening soon Specimen collection for participants due for colorectal cancer screening, surveillance, or treatment: IMPACT (PI Hubbard).

Survey Studies 

Cannabis Use During Cancer Therapy: This study aims to implement provider evaluation of oncology patients' cannabis use at Allina Health Cancer Institute, thereby ensuring patient safety and treatment efficacy (PI Preedit). *Only available in Minneapolis

GSK4057190: Qualitative research study to understand the patient experience of colorectal cancer (PI Hubbard).

Other

GRN BioBank Initiative: Opening soon The Guardian BioBank Initiative: accelerating clinical research and access to clinical trials (PI Datta).

If you are interested in more information regarding the previous studies, please call the Allina Health Cancer Institute Research Bridge Line: 612-863-8716

Metropolitan Heart & Vascular Institute

Learn more about the Metropolitan Heart & Vascular Institute clinical trials.

Allina Health Minneapolis Heart Institute

Study name: Multicenter Imaging in Lead Extraction Study (MILES)
Study summary: The primary objectives of this registry is to correlate the amount of fibrosis as documented on Electrocardiogram (ECG) gated Computed Tomography (CT) scans with ease of advancing sheaths over the leads through the SVC zone during lead extraction.
Contact: Katie Bisch, katie.bisch@allina.com, 651-241-2913651-241-2913
More information: https://clinicaltrials.gov/ct2/show/NCT03772704

Study name: Reducing Lung Congestion Symptoms in Advanced Heart Failure (RELIEVE-HF)
Study summary: The objective of the RELIEVE-HF study is to provide reasonable assurance of safety and effectiveness of the V-Wave Interatrial Shunt System by improving meaningful clinical outcomes in patients with New York Heart Association (NYHA) functional class III or ambulatory class IV heart failure (HF), irrespective of left ventricular ejection fraction, who at baseline are treated with guideline-directed drug and device therapies.
Contact: Katie Schwister, katie.schwister@allina.com, 651-241-2816651-241-2816
More information: https://clinicaltrials.gov/ct2/show/NCT03499236

Study name: The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia (SAVAL)
Study summary: Two phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs. percutaneous transluminal angioplasty (PTA).
Contact: Nikki Gernes, nicole.gernes@allina.com, 651-241-2216651-241-2216
More information: https://clinicaltrials.gov/ct2/show/NCT03551496

Study name: Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (SOLVE CRT)
Study summary: This study is a prospective, multi-center, randomized, controlled, double blinded, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.
Contact: Nikki Gernes, nicole.gernes@allina.com, 651-241-2216651-241-2216
More information: https://clinicaltrials.gov/ct2/show/NCT02922036

Study name: Narrow QRS HF Patients Assessed by ECG Belt
Study summary: The purpose of this study is to quantitate electrical dyssynchrony in heart failure (HF) patients with a narrow QRS complexes (≤ 130 ms) using the ECG Belt. This is a pilot study that is designed to provide data that can be used in designing and implementing a prospective study of cardiac resynchronization therapy (CRT) in narrow QRS patients selected and optimized using the ECG Belt.
Contact: Chris Brown, christopher.brown2@alllina.com, 651-241-2806651-241-2806
More information: https://clinicaltrials.gov/ct2/show/NCT03367104

Study name: ECG Belt vs. Echocardiographic Optimization of CRT
Study summary: Cardiac resynchronization therapy (CRT) has been a valuable intervention for patients with systolic heart failure for over 15 years. Despite years of research, there is a still a 25-40% non-responder rate depending on the outcomes measured. CRT optimization is a term used to describe the act of individualizing the therapy (CRT programming) for an individual patient. This is not often performed, but when it is, echocardiography is utilized. Recent work of body surface mapping using a novel system called the ECG Belt has shown a relationship between measures of electrical dyssynchrony and acute and chronic heart pumping function. This study will compare outcomes of patients randomized to either echocardiographic or ECG Belt optimization of CRT devices.
Contact: Chris Brown, christopher.brown2@alllina.com, 651-241-2806651-241-2806
More information: https://clinicaltrials.gov/ct2/show/NCT03305692

No current clinical trials.

No current clinical trials.

If you are interested in learning more about any Neuroscience Research trials, please contact the Neuroscience Research Team at NeuroscienceResearch@allina.com

Neuro-Oncology Research Trials:

GBM AGILE: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM).

Summary:

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. 

More Information: https://clinicaltrials.gov/ct2/show/NCT03970447

 

STaRT Registry: A Multicenter Observational Study of GammaTile™ Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms.

Summary:

This is a registry study aimed at evaluating real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of GammaTiles.

More Information: https://clinicaltrials.gov/ct2/show/NCT04427384

 

EF-32 (TRIDENT): A Pivotal, Randomized, Open-Label Study of OPTUNE® (TTFIELDS, 200KHZ) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma.

Summary:

This study is designed to test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.

More Information: https://clinicaltrials.gov/ct2/show/NCT04471844

 ROADS: GTM-102- A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors. 

Summary:
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.

More Information: https://clinicaltrials.gov/study/NCT04365374

Neuro-interventional Radiology Research Trials:

WEB-PAS: Post-Market Surveillance Study to Evaluate the Long Term Safety and Effectiveness of the WEB® Device.

Summary:

This is a Post-Market Surveillance study of the FDA-approved WEB Device. The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant.

More Information: https://clinicaltrials.gov/ct2/show/NCT04839705

 

THUNDER: Acute Ischemic Stroke Study with the Penumbra System® including Thunderbolt™ Aspiration Tubing.

Summary:

The objective of this study is to demonstrate the safety and efficacy of the Penumbra System including Thunderbolt Aspiration Tubing (Thunderbolt) in a population presenting with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion (LVO) who are eligible for mechanical thrombectomy.

More Information: https://clinicaltrials.gov/ct2/show/NCT05437055

 

PRECISE: Perfusion imaging to identify posterior circulation candidates for thrombectomy

Summary:

Strokes are often caused by a blood clot inside a blood vessel that blocks the normal blood flow to a part of the brain; this type of stroke is called an ischemic stroke. The blockage can result in permanent brain damage. We are looking to enroll participants with an ischemic stroke due to a blockage of one of the vessels that supplies blood to the back of the brain. The purpose is to find out if advanced brain imaging can help identify which participants are most likely to benefit from a procedure to remove the blood clot to restore the blood flow to the brain.

RESTORE: Real-World Analyses of Stroke-Thrombus Occlusion Retrieval

Summary:

To collect real-world evidence allowing assessment of functional, imaging, and safety outcomes of MicroVention market-released acute ischemic stroke devices when used at the direction of the treating physician.

 More information: https://clinicaltrials.gov/study/NCT04451525

CAR: Complex Aneurysm Registry: Real-World Evidence Data Collection for Intracranial Aneurysm Treatment Devices.

Summary

To collect real-world evidence allowing assessment of functional, imaging, and safety outcomes of commercially available MicroVention devices used for the endovascular treatment of intracranial aneurysms (IA) at the direction of the treating physician.

More Information: https://clinicaltrials.gov/study/NCT06215105

Stroke Research Trials:

 ASPIRE: Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery.

Summary:

ASPIRE is a randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of  apixaban (Eliquis®), compared with aspirin, in patients with a recent ICH and high-risk non-valvular AF . Patients will be enrolled over 3.5 years and followed for study outcomes for a minimum of 12 months and maximum of 36 months.

More information: https://clinicaltrials.gov/ct2/show/NCT03907046

 CAPTIVA: Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis.

Summary

The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.

More Information: https://clinicaltrials.gov/study/NCT05047172

 SISTER: Strategy for Improving Stroke Treatment Response.

 Summary

SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.

More Information: https://clinicaltrials.gov/study/NCT05948566

No current clinical trials.

If you are interested in participating in any Courage Kenny Research Studies, please contact CKResearch@allina.com

Current Studies List:

Clinical implementation of wearable sensors to measure dual-task motor function in individuals with mild traumatic brain injury. [Principal Investigator: Margaret Weightman, PT, PhD]

The utility of sensor-based dual-task assessments has been established but has not yet been translated into standard clinical practice. This study seeks to determine whether a Physical Therapist can reasonably conduct these sensor-based assessments in traditional PT clinical sessions. 

Feasibility of a Purpose in Life Renewal Intervention for Adults With Persistent Symptoms After Concussion (PSC). [Principal Investigator: Mary Radomski, PhD, OTR/L]

A team composed of researchers from Courage Kenny Rehabilitation Institute (CKRI) propose to recruit a sample of individuals experiencing persistent symptoms after concussion to evaluate the efficacy of administering the Compass Course to a novel population, to improve psychological well-being, engagement in everyday activities, and purpose in life.

MENTOR - A MNSCIMS Project. [Principal Investigator: Amanda DeRasmi, DO]

As part of the MNSCIMS consortium, Courage Kenny Research is operating the MENTOR project, which seeks to validate a clinical tool to describe bowel dysfunction in the inpatient rehabilitation setting and facilitate management across the first-year post-injury.

Minnesota Regional Spinal Cord Injury Model System of Care. [Principal Investigator: Shraddha Srivastava, PhD]

Courage Kenny Rehabilitation Institute has recently been designated as part of the Minnesota Regional Spinal Cord Injury Model Systems. This is one of 14 U.S. spinal cord model systems of care that received 5-year research funding from the U.S. Department of Health and Human Services National Institute on Disability, Independent Living, and Rehabilitation Research. 

Reading after Traumatic Brain Injury: Preliminary Development of a Guiding Model for Assessment and Treatment. [Principal Investigator: Katy H. O'Brien, PhD, CCC-SLP]

Adults with traumatic brain injury are being invited to participate in a study which looks at the reading experiences of patients with TBI. In particular, this project looks to describe the reading experiences of adults with TBI, including habits, barriers, and facilitators.

SENSE - Feasibility of using continuous, remote symptom monitoring to identify and respond to early fall-risk for patients with chemotherapy-induced peripheral neuropathy. [Principal Investigator: Laura Gilchrist, PT, PhD]

This study is looking at using remote symptom monitoring to determine the relationship between chemotherapy-induced peripheral neuropathy and fall risk. Participants treated at Allina Health will use a mobile ecological momentary assessment (mEMA) to provide real-time feedback on symptom status. 

Validity and Reliability of the Courage-Kenny Fibrosis Grading Scale for Post- Cancer Treatment Effects in Survivors of Breast and Head and Neck Cancer. [Principal Investigator: Margaret Weightman, PT, PhD]

The goal of this project is to refine and test the validity and feasibility of the Courage Kenny Fibrosis Grading Scale (CK-FGS), a test purported to quantify the degree of cancer-related tissue fibrosis experienced by those who have undergone surgery and radiation for various cancers. 

Provider Communication in Rehabilitation Open Patient Encounter Notes (ReOPEN): Application to Neurorehabilitation for Traumatic Brain Injury. [Principal Investigator: Katy H. O'Brien, PhD, CCC-SLP]

Electronic health record notes generated by healthcare providers are available for patients to read, with the goal of better understanding their care. This study develops a replicable methodology to evaluate stigmatizing language and linguistic complexity in rehabilitation notes, then extends this to characterize how people with brain injury, a population known to experience difficulty reading, react to and benefit from reading such notes.

Increased mental effort is often reported by people with a history of brain injury as a significant barrier to doing as much as they used to do before their injury. The goal of this project is to demonstrate that we can measure effort objectively and precisely using pupillometry and to identify how effort has changed as a result of brain injury.

Personalized Cognitive Rehabilitation: Validating a Brief Clinical Assessment of Multiple Memory Systems. [Principal Investigator: Natalie Covington, PhD, CCC-SLP]

Rehabilitation for brain injury requires learning and memory, but each person with TBI is different in terms of how their memory has changed. In this study, we are testing whether a set of novel memory tests can help us to predict what kind of treatment works best for individual people with TBI.

Score Agreement of Two Devices that Assess Readiness for Behind-the-Wheel Assessment for Persons with Acquired Brain Injury [Principal Investigator: Sharon Gowdy Wagener OTD, Co-Principal Investigator: Alisa Kocian, MA, OTR/l]

Courage Kenny Rehabilitation Institute is transitioning from using the Dynavision 2 to the Bioness Integrated Therapy System (BITS) as a tool to inform driving readiness recommendations related to visual-motor reaction time. At present, there is minimal research to inform score interpretation of the BITS related to community mobility. This research study will explore score agreement between the two devices to support further research and assist therapists in their assessment and recommendations for patients returning to safe driving.

 

 

No current clinical trials.

Utility of Intermittent Cryo-Compression versus Traditional Icing Following Arthroscopic Rotator Cuff Repair [Principal Investigator: L. Pearce McCarty III, MD, Co-Investigator: Lauren Zurek, MD]

 

The study proposes to evaluate the utilization of a non-invasive, novel cryo – compression, post-operative modality to improve pain control versus standard ice wraps in the immediate post-operative phase of arthroscopic rotator cuff surgery via a randomized controlled study design. 

Tornier Shoulder Outcomes Study to Examine Safety and Functional Outcomes in Shoulder Arthroplasty and Fracture Patients  
Study summary: The Tornier Shoulder Outcomes Study is designed to collect safety and efficacy data on designated commercially available Tornier Shoulder repair products. In addition, this study will provide performance data for use in education, marketing materials, peer-reviewed publications and support research and development of future products
More information: https://clinicaltrials.gov/ct2/show/NCT02047955

Contact: Ned Tervola, ned.tervola@allina.com, 952-914-8594952-914-8594;